A parent who refuses to hear their Alzheimer's test result is exercising a documented preference, not an unusual one. In a Washington University Bioethics Research Center study of 274 cognitively unimpaired adults over 65, 40% declined to learn their own Alzheimer's biomarker results, a choice researchers described as exercising a "right not to know," according to a study reported by Patient Care Online. That means a parent who says "don't tell me" is behaving like a sizable minority of older adults, not acting irrationally. The rest of this covers why people make that choice, how family history shapes it, what the difference is between refusing to know and genuinely being unable to grasp a result, and what a family can do in response.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why So Many People Choose Not to Know
- Is This Denial, or Something the Disease Itself Is Causing?
- What the Medical and Ethics Guidance Actually Says
- What Changed With Blood Tests, and Why That Doesn't Force the Issue
- What Families Can Actually Do
Why So Many People Choose Not to Know
Declining a result is not rare, and it is not random. The same Patient Care Online coverage of the WashU study found that Black participants were nearly twice as likely as White participants to decline, and people who already had a parent with Alzheimer's dementia were 49% more likely to decline than those with no family history. A parent who watched their own mother or father decline from Alzheimer's may be reacting to that memory, not to the test itself. The reasons people give are consistent.
According to Inside Precision Medicine's coverage of the same research, people who decline most often cite the absence of an effective treatment, fear of the anxiety a result would cause, and worry about becoming a burden on their family. Several told researchers that a proven treatment becoming available could change their answer — the refusal is tied to today's options, not a fixed personality trait. Stated intentions do not always match real decisions. A separate cognitively normal volunteer cohort found that 81% said beforehand they wanted to learn their Alzheimer's risk estimate, but only 60% actually chose to receive it when the real decision arrived, according to NeuroscienceNews' coverage of the risk-disclosure study. A parent who once said they'd want to know may still change their mind when the envelope is actually in front of them.
Is This Denial, or Something the Disease Itself Is Causing?
Families often assume a parent's refusal is stubbornness, but the Alzheimer's Association draws a sharp clinical line between two different things. Anosognosia is unawareness caused by changes in the brain itself, so the person genuinely cannot perceive that anything is wrong. Denial is different: the person is aware of the diagnosis but psychologically refuses to accept it, according to the Alzheimer's Association's explanation of anosognosia. The distinction matters because the two call for different responses.
Someone with anosognosia cannot be reasoned into awareness, since the deficit is neurological, not emotional. Someone in denial is processing a hard truth on their own timeline, which argument tends to entrench rather than dissolve. A parent who refuses to hear a test result before testing even happens is not the same as a parent who has already been diagnosed and will not discuss it. The first is a competent decision about future information. The second may involve either denial or anosognosia, and telling the two apart usually requires the judgment of the medical team already treating the parent.
What the Medical and Ethics Guidance Actually Says
Physicians are not left without direction here. The American Medical Association's guidance states a dementia diagnosis should be given directly to the patient "if at all possible," though commentary on the guidance notes it does not spell out how to handle a patient's explicit, competent refusal to hear the results, according to a Relias Media summary of the AMA guidelines. That gap is exactly where a parent's refusal lands: the guidance favors disclosure in general but does not override a clear "no." Alzheimer Europe's position paper goes further on this specific point, stating that a clear refusal by a person with dementia to have the diagnosis shared with third parties should be respected regardless of their level of incapacity, unless doing so is clearly not in that person's best interest, according to Alzheimer Europe's position paper on disclosure.
In practice, that means a parent's wish not to know, or not to have the result shared further, is generally something the care team works around rather than overrides. This caution isn't new or specific to biomarker testing. The Alzheimer's Association's 2015 Facts and Figures report found only 45% of people with Alzheimer's disease or their caregivers said a doctor told the patient the diagnosis directly, compared with more than 90% disclosure rates for the four most common cancers, according to reporting on the Facts and Figures findings. Reluctance to deliver this particular diagnosis plainly predates any individual patient's refusal.
What Changed With Blood Tests, and Why That Doesn't Force the Issue
Some families assume newer, simpler testing changes the calculus. The FDA cleared the first blood test for Alzheimer's, Lumipulse, in May 2025, measuring plasma pTau217 and beta-amyloid 1-42 in adults 55 and older who have memory symptoms, as an aid used alongside other evaluation rather than a standalone diagnostic; a second blood test built for primary-care use was cleared in October 2025, according to BrainFacts.org's coverage of the FDA clearances.
A simpler blood draw does not make the result any less something the parent is entitled to decline. Nothing about an easier test changes the ethical ground rules above: a competent adult's refusal to hear a result still gets the same deference, blood test or spinal tap or PET scan. If anything, easier testing raises the odds a parent will be offered the choice at all, making the refusal conversation more common, not less fraught.
What Families Can Actually Do
When a parent won't discuss a diagnosis or a pending result, the Alzheimer's Foundation of America recommends against arguing, debating, or quizzing them about it — confrontation tends to harden the resistance rather than resolve it, according to the Alzheimer's Foundation of America's caregiver guidance. A few concrete steps follow from that guidance: A parent's "I don't want to know" is, by the numbers, close to a coin flip's worth of their peers making the same choice. Respecting it, while keeping the door open for them to change their mind later, matches both the ethics guidance and what researchers have actually observed people do.
- Put key decisions in writing. A parent who agrees to something verbally may not recall doing so later, so written records protect everyone, including the parent.
- Don't force the conversation on a single timetable. Interest in knowing can shift, as the 81%-to-60% gap in stated versus actual decisions shows — revisiting the question later sometimes gets a different answer.
- Loop in the medical team as the disease progresses. The approach that works at the point of testing may not work once symptoms advance, and the same AFA guidance notes the strategy needs to evolve rather than stay fixed.
- Separate the test result from the relationship. A parent declining to hear a biomarker result is making a choice about information, not rejecting the family member who raised the subject.
